EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products



Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products



Official Gazette of the United States Patent & Trademark Office Patents 1274(3), Sep 16



The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.

(PDF 0-2 workdays service: $29.90)

Accession: 035980540

Download citation: RISBibTeXText



Related references

Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein. Inflammatory Bowel Diseases 10(6): 763-770, 2005

Therapeutic uses of bactericidal/permeability increasing protein products. Official Gazette of the United States Patent & Trademark Office Patents 1199(3): 1919, June 17, 1997

Therapeutic uses of bactericidal/permeability-increasing protein dimer products. Official Gazette of the United States Patent & Trademark Office Patents 1249(3), Aug 21, 2001

Human therapeutic uses of bactericidal/permeability increasing protein products. Official Gazette of the United States Patent & Trademark Office Patents 1200(1): 443, July 1, 1997

Therapeutic compositions comprising bactericidal/permeability-increasing protein products. Official Gazette of the United States Patent & Trademark Office Patents 1223(3), Jun 15, 1999

Stable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same. Official Gazette of the United States Patent & Trademark Office Patents 1261(2), Aug 13, 2002

Therapeutic uses of bactericidal/permeability increasing protein protein products. Official Gazette of the United States Patent & Trademark Office Patents 1214(3): 2938, Sept 15, 1998

Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases. Medizinische Klinik 92(7): 389-393, 1997

Bactericidal permeability increasing protein gene polymorphism is associated with inflammatory bowel diseases in the Turkish population. Saudi Journal of Gastroenterology 21(4): 239-244, 2016

Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing protein product and antibiotic. Official Gazette of the United States Patent & Trademark Office Patents 1239(5), Oct 31, 2000

Isolation from rabbit granulocytes of a novel non bactericidal 15kda protein that potentiates the antibacterial activities of the bactericidal permeability increasing protein bpi. Clinical Research 37(2): 567A, 1989

Lipopolysaccharide binding protein greatly potentiates bactericidal activity of recombinant bactericidal permeability-increasing protein. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 34(0): 224, 1994

Bactericidal permeability increasing protein as a novel therapeutic modality in the treatment of endotoxic shock. Clinical Research 39(2): 351A, 1991

Role of bactericidal permeability-increasing protein in the treatment of gram-negative pneumonia. Surgery 114(2): 140-146, 1993

Importance of the residue 190 on bactericidal activity of the bactericidal/permeability-increasing protein 5. Oncotarget 7(28): 43088-43094, 2016